AKT1 and melanoma: Moreover, PI3K-AKT and MEK-ERK signaling pathway were suppressed in resistant A375R cells (Fig. 5I), which suggested PI3K-AKT and MEK-ERK signalings might not be responsible for vemurafenib resistance in melanoma.